Clinical Trials

Clinical Research at RVC

Retina Vitreous Center is active in Clinical Research since 2013 and participating in various clinical trials sponsored by NIH and Industry.

The DRCR Network (DRCR.net) is a collaborative network dedicated to facilitating multicenter clinical research of diabetic retinopathy, age-related macular degeneration (AMD), hereditary retinal degenerations and other retinal diseases.

The DRCR.net was formed in September 2002 and currently includes over 115 participating sites with over 400 physicians throughout the United States. The DRCR.net is funded by the National Eye Institute (NEI). The NEI is a part of the National Institutes of Health, which is the branch of government that funds medical research. Retina Vitreous Center is recognized as a Top Site for the year 2015 by the DRCR.net and the only private practice site in Oklahoma.

Dr. Shah, Dr Phelps, and Dr. Ridges serve as investigators for the site and are excited to offer our patients novel treatment and approaches in retinal disease.

Studies completed:
  • DRCR Protocol T
  • Allegro PVD-202
  • La Roche-BP28248
  • Orbit TG-MV-018
  • Pfizer MS B4351002
  • Pronova CTN 401613201
  • Merck MK-8931 PN017
Studies currently enrolling:
  • DRCR Protocol AB
  • DRCR Gene Study
  • Aerpio Time2b
If you are patient and interested to participate in clinical trials or If you are monitor looking for our site to participate in any new or ongoing clinical trials:

Contact Information:
Mr. Romesh
Clinical Research Coordinator
Phone: (406) 607-6699 x 111
Email: Romesh@rvcoklahoma.com
Clinical Research at RVC
Retina Vitreous Center is active in clinical research since 2013 and participating in various clinical trials sponsored by National Institutes of Health (NIH) and industry. We believe patient access to the newest treatment options helps us provide the highest level of care to our patients.

Many of our patients travel from far away locations in Oklahoma to participate in the latest treatments for sight threatening diseases.

Why should you participate in clinical trials? Read this article written by the NIH.

We are proud to be a part of is the DRCR Retina Network which was formed in September 2002 and currently includes over 115 participating sites with over 400 physicians throughout the United States. The DRCR Retina Network is funded by the National Eye Institute (NEI). The NEI is a part of the National Institutes of Health, which is the branch of government that funds medical research. Retina Vitreous Center has been nationally recognized for receiving the Quality research award for the year 2015, 2017, and 2018 by the DRCR Retina Network. RVC physicians have contributed clinically in multiple studies that were published in prestigious journals such as New England Journal of Medicine, Journal of the American Medical Association, and Ophthalmology and data of which was presented at national and international ophthalmology meetings. The results of these pivotal trials have affected the standard of care provided by retinal specialists across the world.


Dr. Shah, Dr Phelps, Dr. Ridges, and Dr. Hood serve as investigators for the site and are excited to offer our patients novel treatment and approaches in retinal disease. Studies completed:
• DRCR Protocol T
• DRCR Protocol V
• Allegro PVD-202
• La Roche-BP28248
• Orbit TG-MV-018
• Pfizer MS B4351002
• Pronova CTN 401613201
• Merck MK-8931 PN017
• Aerpio Time2b


Studies currently ongoing or enrolling (to learn more click on hyperlink):
• Diabetic Macular Edema - DRCR Protocol AE
• Vitreous Hemorrhage in Diabetic Retinopathy - DRCR Protocol AB
• Pneumatic Vitreolysis for Vitreomacular Traction - DRCR Protocol AG
• Pneumatic Vitreolysis for Macular Hole - DRCR Protocol AH
• Diabetic Macular Edema - Genentech YOSEMITE
• Port Delivery System of Lucentis - Genentech ARCHWAY<
• Dry AMD – Geographic Atrophy – Apellis OAKS
• DRCR Gene Study

If you are patient interested in participating in our ongoing clinical trials or if you are monitor looking for a suitable site to consider participation in a new clinical trial, we appreciate you reaching us: Contact Information: Phone: (406) 607-6699 Email: research@rvcoklahoma.com